Actelion Ltd, the Swiss specialist pharmaceutical company, reported a 26.1% increase to CHF 405.6 million in net revenues for the first quarter as a result of continuing strong sales of Tracleer (bosentan), a treatment for pulmonary arterial hypertension (PAH). Tracleer sales rose by 22.5% to CHF 352.2 million and accounted for about 87% of first quarter revenue.
Privately-owned CellCentric of Cambridge, UK, has secured an agreement with the Center for Genomic Regulation in Barcelona, Spain giving it access to intellectual property generated by Professors Ramin Shiekhattar and Luciano Di Croce in epigenetics.
Renovo Group Plc’s lead product for wound-healing, avotermin, has been highlighted by an editorialist in The Lancet as having possible further applications for a range of fibrotic disorders. The drug recently entered a Phase 3 trial for use in scar revision surgery.
Galápagos NV has signed a new multi-year research deal with Merck & Co to discover small molecule candidate drugs with potential for treating inflammatory diseases. The deal is the company’s second alliance with Merck this year.
GlaxoSmithKline Plc and Pfizer Inc have announced plans to put their assets in the area of HIV medicine into a new company that will concentrate on research and development in this disease area
Pharming Group NV is the latest European company to enter into an equity funding agreement with YA Global of the US giving it an option to issue up to a total of €20 million in Pharming shares at any time during the next 36 months.
After refocusing its business on the therapeutic areas of oncology and immunology, MediGene now expects to conclude a development and marketing partnership in 2009 for its product for pancreatic cancer, EndoTAG-1.
The UK publicly-funded Medical Research Council has announced the setting up of a new centre in London that will produce ‘drug-like’ molecules with the potential to become therapies. The centre will have an initial operating budget of £6 million.
The European Medicines Agency and Health Canada have fleshed out the details of a confidentiality agreement under which the agencies can exchange confidential information about pending legislation and licensing applications from companies.
Silence Therapeutics Plc has applied to the German regulator to bring its short-interfering RNA molecule (siRNA) for solid tumours into a first-in-man study. If approved, it would be the company’s first internal candidate in the clinic.